23-NHL-32-CT-PMC: CNTY-101-111-01, The ELiPSE-1 Study: A Phase 1, Multicenter, Open-Label Study of CNTY-101 in Subjects With Relapsed or Refractory CD19-Positive B-Cell Malignancies

Grants and Contracts Details

StatusActive
Effective start/end date11/2/23 → 11/2/25

Funding

  • Century Therapeutics Incorporated: $235,488.00